New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
05:38 EDTVSIVitamin Shoppe acquires FDC Vitamins for $85M
Vitamin Shoppe announced that it has purchased FDC Vitamins, doing business as Nutri-Force Nutrition, a contract manufacturer of vitamins, minerals and supplements from MBF Healthcare Partners, and other minority holders. Nutri-Force is a current manufacturer for the company as well as for other domestic and international customers and distributors. The transaction was structured as a purchase of FDC Vitamins, equity by a wholly-owned subsidiary of the Vitamin Shoppe. The purchase price is approximately $85M which includes a $5M earn out based on 2014 financial performance. The purchase price will be paid with available cash. The acquisition of Nutri-Force is expected to be neutral to slightly accretive to 2014 EPS, excluding transaction and integration costs.
News For VSI From The Last 14 Days
Check below for free stories on VSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
09:17 EDTVSIOn The Fly: Pre-market Movers
Subscribe for More Information
July 28, 2014
07:36 EDTVSIVitamin Shoppe comps should should show acceleration, says RW Baird
Baird expects Q2 earnings at Vitamin Shoppe to be in-line but believes its comparable sales should show an acceleration and an improved margin performance relative to prior quarters. The firm also believes concerns over increased promotional activity are overblown. Baird likes the stock at current levels and keeps a Buy rating with a $55 price target on the shares.
July 21, 2014
06:19 EDTVSIVitamin Shoppe recommended ahead of Q2 report at Goldman
Goldman believes Vitamin Shoppe (VSI) competitive pressures are overblown and that the company has relatively low overlap with GNC (GNC) and that recent price cuts have had minimal impact. The firm expects Vitamin Shoppe's Q2 to mark the beginning of sharp earnings acceleration and better execution and recommends buying shares ahead of the Q2 report. Shares are rated Conviction Buy with a $60 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use